Eikon Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Public

  • Employees
  • 384

Employees

  • Stock Symbol
  • EIKN

Stock Symbol

  • Share Price
  • $4.77
  • (As of Thursday Closing)

Eikon Therapeutics General Information

Description

Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

Contact Information

Website
www.eikontx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 230 Harriet Tubman Way
  • Millbrae, CA 94030
  • United States
+1 (341)
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 230 Harriet Tubman Way
  • Millbrae, CA 94030
  • United States
+1 (341)

Eikon Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eikon Therapeutics Stock Performance

As of 19-Nov-2026, Eikon Therapeutics’s stock price is $4.77. Its current market cap is $258M with 54.2M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.77 $5.17 $4.72 - $17.40 $258M 54.2M 558K -$7.86

Eikon Therapeutics Financials Summary

As of 30-Sep-2026, Eikon Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 156,528
Revenue 0 0 0 0
EBITDA (334,291) (314,801) (234,954) (247,947)
Net Income (337,134) (324,248) (243,814) (241,997)
Total Assets 706,201 594,734 491,240 525,705
Total Debt 249,547 257,319 202,459 31,735
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eikon Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eikon Therapeutics‘s full profile, request access.

Request a free trial

Eikon Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Eikon Therapeutics‘s full profile, request access.

Request a free trial

Eikon Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-int
Drug Discovery
Millbrae, CA
384 As of 2025

Cambridge, MA
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eikon Therapeutics Competitors (56)

One of Eikon Therapeutics’s 56 competitors is Relay Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Relay Therapeutics Formerly VC-backed Cambridge, MA
Pliant Therapeutics Formerly VC-backed San Francisco, CA
Fairjourney Biologics Private Equity-Backed Porto, Portugal
Synlogic Formerly VC-backed Winchester, MA
Valneva Formerly VC-backed Lyon, France
You’re viewing 5 of 56 competitors. Get the full list »

Eikon Therapeutics Patents

Eikon Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026217628-A1 Werner helicase inhibitors for treating dmmr and/or msi-h cancers Pending 08-Apr-2025
WO-2026193291-A1 Synthesis of substituted tricyclic compounds Pending 12-Mar-2025
WO-2026107227-A1 Compositions comprising usp1 inhibitors and methods of using the same Pending 13-Nov-2024
WO-2026006796-A1 Compositions comprising werner syndrome helicase inhibitors and methods of using the same Pending 27-Jun-2024
WO-2025250888-A1 Resiquimod in combination with a pd-1 or pd-l1 antagonist for treating cancer Pending 30-May-2024 A61K31/4745
To view Eikon Therapeutics’s complete patent history, request access »

Eikon Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eikon Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Eikon Therapeutics‘s full profile, request access.

Request a free trial

Eikon Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Eikon Therapeutics’s complete esg history, request access »

Eikon Therapeutics FAQs

  • When was Eikon Therapeutics founded?

    Eikon Therapeutics was founded in 2019.

  • Where is Eikon Therapeutics headquartered?

    Eikon Therapeutics is headquartered in Millbrae, CA.

  • What is the size of Eikon Therapeutics?

    Eikon Therapeutics has 384 total employees.

  • What industry is Eikon Therapeutics in?

    Eikon Therapeutics’s primary industry is Drug Discovery.

  • Is Eikon Therapeutics a private or public company?

    Eikon Therapeutics is a Public company.

  • What is Eikon Therapeutics’s stock symbol?

    The ticker symbol for Eikon Therapeutics is EIKN.

  • What is the current stock price of Eikon Therapeutics?

    As of 19-Nov-2026 the stock price of Eikon Therapeutics is $4.77.

  • What is the current market cap of Eikon Therapeutics?

    The current market capitalization of Eikon Therapeutics is $258M.

  • Who are Eikon Therapeutics’s competitors?

    Relay Therapeutics, Pliant Therapeutics, Fairjourney Biologics, Synlogic, and Valneva are some of the 56 competitors of Eikon Therapeutics.

  • What is Eikon Therapeutics’s annual earnings per share (EPS)?

    Eikon Therapeutics’s EPS for 12 months was -$7.86.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process